Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H27NO3 |
| Molecular Weight | 425.5189 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(=C1)C2=CC3=C(C=C2)N(CC4=CC=C(C=C4)C(C)(C)C)C=C3C(=O)C(O)=O
InChI
InChIKey=HSXLMAFNWCSZGP-UHFFFAOYSA-N
InChI=1S/C28H27NO3/c1-18-6-5-7-20(14-18)21-10-13-25-23(15-21)24(26(30)27(31)32)17-29(25)16-19-8-11-22(12-9-19)28(2,3)4/h5-15,17H,16H2,1-4H3,(H,31,32)
| Molecular Formula | C28H27NO3 |
| Molecular Weight | 425.5189 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Wyeth was developing the small molecule plasminogen activator inhibitor-1 (PAI-1) antagonist aleplasinin for the treatment of Alzheimer's disease in the US. PAZ-417 inhibits PAI-I (Plasminogen activator inhibitor-1), thereby increasing the activation of plasminogen to form plasmin. There is some evidence that plasmin can increase the cleavage of amyloid precursor protein at the alpha cleavage site, which could reduce the formation or increase the clearance of amyloid beta, a suspected culprit in Alzheimer's disease. However, it`s development for Alzheimer's disease treatment was discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:06:10 UTC 2023
by
admin
on
Fri Dec 15 16:06:10 UTC 2023
|
| Record UNII |
LL56J87F3X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C783
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10224267
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
CHEMBL325424
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
TT-15
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
481629-87-2
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
C76071
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
300000034037
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
8939
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
DB12635
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
DTXSID80197447
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY | |||
|
LL56J87F3X
Created by
admin on Fri Dec 15 16:06:10 UTC 2023 , Edited by admin on Fri Dec 15 16:06:10 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
